The type V cyclic GMP phosphodiesterase was partially purified from the high-speed supernatant of guinea-pig lung. The isoenzyme displayed linear kinetics for cyclic GMP hydrolysis, with Km = 2.2 ± 0.2 ,tM and Vmax = 1.2 ± 0.08 nmol/ min per mg. The selective type V phosphodiesterase inhibitor Zaprinast inhibited cyclic GMP hydrolysis with IC50 (concn. giving 50 % inhibition) = 0.45 + 0.08 /,M. Isobutylmethylxanthine promoted a 3-fold increase in the binding of cyclic GMP to the isoenzyme. The addition of the catalytic subunit of protein kinase A to an activation cocktail containing the partially purified type V phosphodiesterase resulted in a marked increase in Vmax for cyclic GMP hydrolysis (-10-fold at 40 units of protein kinase A). We have suggested that protein kinase A triggers phosphorylation of the phosphodiesterase, which results in activation of phosphodiesterase activity. In addition, the sensitivity to inhibition by Zaprinast is severely decreased (the IC50 for inhibition is 7.5 + 1.1 ,uM), suggesting that the potency of phosphodiesterase inhibitors is effected by phosphorylation of the enzyme.
INTRODUCTION
Cyclic AMP and cyclic GMP phosphodiesterases exist as a family of isoenzymes which possess distinct primary amino acid sequences and are encoded by distinct genes (Beavo & Reifsnyder, 1990) . These multiple enzymes have been classified into five major groups according to kinetic, physical, immunological and regulatory properties (for review see Beavo & Reifsnyder, 1990) . The phosphodiesterase plays a pivotal role in the cellular signalling process, limiting the cellular response to agents which utilize cyclic nucleotides as second messengers. However, these isoenzymes do not solely act as a brake on cyclic nucleotide synthesis, since their activity states are also regulated by a variety of hormones such as insulin, adrenaline, glucagon, prostaglandin 12 and prostaglandin E1 (Zinman & Hollenberg, 1974; Loten et al., 1978; Makino & Kono, 1980; Heyworth et al., 1983; Macphee et al., 1988) . The molecular events which lead to stimulation of phosphodiesterase activity result in the establishment of a new intracellular steady state of the cyclic nucleotide, alteration in the activity status of protein kinases A and G and inhibition of socalled resting-state cellular processes. The molecular mechanisms by which hormones trigger the modulation of phosphodiesterase activity is via the action of specific protein kinases.
In this regard, several phosphodiesterases have been shown to be phosphorylated by several different protein kinases. For instance, the brain type I Ca2+/calmodulin-activated phosphodiesterase exists as two isoforms: one, of 63 kDa, is a substrate for a Ca2+/calmodulin-dependent protein kinase, whereas the other, a 61 kDa species, is phosphorylated by protein kinase A (Sharma & Wang, 1986) . The type III cyclic GMP-inhibited cyclic AMP phosphodiesterase is also a substrate for protein kinase A (Harrison et al., 1986; Kilgour et al., 1989) , the phosphorylation of this isoenzyme leading to a profound activation of cyclic AMP phosphodiesterase activity. The type IV cyclic AMP-specific phosphodiesterase has been shown to be phosphorylated and activated by the insulin-receptor tyrosine kinase in intact hepatocytes (Pyne et al., 1989) . Finally, the type V cyclic GMPspecific phosphodiesterase is a substrate for phosphorylation by both protein kinase G and protein kinase A. The magnitude of phosphorylation is dependent on the binding of cylic GMP to a non-catalytic site in the phosphodiesterase (Thomas et al., 1990a,b) . However, as yet no subsequent activity changes have been observed upon phosphorylation of this isoenzyme by either kinase.
In this paper, we report that the catalytic subunit of protein kinase A triggers phosphorylation and activation of the type V phosphodiesterase from guinea-pig lung. In addition, we have characterized the effect of this phosphorylation on both kinetic and inhibitor properties of this phosphodiesterase. These results suggest that, in the lung, a level of cross-talk between cellular signalling processes utilizing cyclic AMP and cyclic GMP exists.
MATERIALS AND METHODS Materials
The purified catalytic subunit of protein kinase A was purchased from Sigma Chemical Co. (Poole, Dorset, U.K.); its purity was > 95 %. Cyclic [8-3H] For incubations with protein kinase C, the cyclic GMP phosphodiesterase (30 ,ug) was combined with an activation cocktail containing (final concns.) 25 mM-Hepes, pH 7.5, 5 mmMgCl2, 0.75 mM-CaC12 and 25 /tM-ATP. To this activation cocktail was added phosphatidylserine (50,g/ml), which had been previously sonicated in 10 mM-Tris/HCl, pH 7.4. To initiate the reaction, purified protein kinase C (0.3 unit; 1 unit = 1 nmol of 32P incorporated/min) was added and the incubation performed at 37 OC for 20 min. Reactions were terminated by placing samples on ice at 4°C. Samples were then removed for assay of cyclic GMP phosphodiesterase. The protein kinase C was stored at -20 0C in 10 mM-Tris / HCI (pH 7.4) / 0.5 mM-EGTA / 0.5mM-EDTA / lOmM-/-mercaptoethanol / 10% (v/v) glycerol/0.05% Triton X-100 and 400 mM-NaCl. In incubations where no kinase was added, the components of the storage buffer were added to the incubation cocktail.
Purification procedure
Step 1: preparation of high-speed supernatant. Routinely one lung (perfused in Krebs-Henseleit buffer, pH 7.4) was removed from a guinea pig and homogenized in buffer A (containing 20 mM-sodium phosphate, pH 6.8, 2 mM-EDTA and 25 mM-flmercaptoethanol) with a Turrex homogenizer (4-5 strokes, up and down). All procedures were performed at 4°C, unless otherwise stated. The homogenate was filtered through cheesecloth and centrifuged at 10000 rev./min for 10 min in a SW 55.2 rotor. The resulting high-speed supernatant was filtered through cheesecloth and taken for chromatography by a modified procedure developed by Francis & Corbin (1988) .
Step 2: chromatography on DEAE-Sepharose column. DEAESepharose was pre-eqilibrated in buffer A, after which the filtered supernatant was loaded on to the column. The DEAE-Sepharose was washed with 6 vol. of buffer A until no protein was eluted, as determined by measurement at 280 nm. The phosphodiesterase activity was then eluted with a 400 ml salt gradient, consisting of buffer A supplemented with 0-0.5 M-NaCl. The fractions were pooled and dialysed against 4 litres of buffer A to remove NaCl.
Step 3: Affi-Gel Blue column. The pooled and dialysed fraction was applied to an Affi-Gel Blue-agarose column (2 cm x 3 cm) which had been previously equilibrated in buffer A. The column was washed sequentially with 6 vol. ofbuffer A, 5 vol. of buffer A + 0.8 M-NaCl, and 5 vol. of buffer A, after which the phosphodiesterase activity was eluted with buffer A+ 0.35M-KSCN. The active fractions were pooled and dialysed against buffer A overnight.
Step 4: zinc chelate absorbent. The pooled enzyme was dialysed for a further 16 h against buffer B containing 20 mmsodium phosphate, pH 6.8, to remove EDTA and mercaptoethanol. The resulting material was loaded on to a 1 ml column of zinc chelate (Boehringer Mannheim) that had been previously equilibrated in 20 mM-sodium phosphate, pH 6.8. The flowthrough fractions containing phosphodiesterase activity were assayed and pooled. Enzyme was stored at -20°C and was stable for 4 weeks.
RESULTS

Partial purification of the type V phosphodiesterase
The cyclic GMP phosphodiesterase activity from guinea-pig lung high-speed supernatants was purified 27-fold by using three chromatographic separation techniques, which included DEAE-Sepharose, Affi-Gel Blue-agarose and zinc chelate absorbant (Table 1) . The cyclic GMP phosphodiesterase activity was eluted from DEAE-Sepharose with a 0-0.5 M-NaCl gradient. A single peak of cyclic GMP phosphodiesterase activity was resolved from this chromatographic column. Phosphodiesterase activity was eluted between 0.1 and 0.2 M-NaCl, and the pooled active fractions had a specific activity of 25 pmol/min per mg at the matrix. A 27-fold purification of cyclic GMP phosphodiesterase activity from the high-speed supernatant was achieved by this procedure (Table 1 ) and the resulting preparation of cyclic GMP phosphodiesterase activity had a specific activity of 236 pmol/min per mg at 0.5 /SM cyclic GMP. The partially purified preparation of phosphodiesterase contained a single isoenzyme, as assessed from first-order-decay exponentials of thermal inactivation at 50°C; t2 values for the phosphodiesterase at 50°C were 1.2 + 0.1 min (Ta2ble 2). Incubation of partially purified cyclic GMP phosphodiesterase (30 ,ug) with activation cocktail containing the catalytic subunit of protein kinase A (1-100 units) resulted in dose-dependent activation of cyclic GMP phosphodiesterase activity (Fig. 2) . At 0.5 /LM-cyclic GMP, the EC50 (concn. giving 50 0 of maximum effect) for activation by protein kinase A was 20 units of catalytic subunit. The maximal stimulation (13-fold) of cyclic GMP phosphodiesterase activity was achieved with 100 units of catalytic sub-unit. The catalytic subunit preparation contained negligible (< 0.1 %) phosphodiesterase activity. Omission of ATP from the activation cocktail decreased the activation of cyclic GMP phosphodiesterase activity (results not shown). Kinetic properties of phosphorylated phosphodiesterase
We have assessed the effect of two specific activities of the catalytic subunit of protein kinase A (40 units and 20 units) on the kinetic properties of the partially purified cyclic GMP phosphodiesterase (Fig. 3, Table 3 ). Addition of 40 units of the catalytic subunit of protein kinase A triggered a 10-fold stimulation ofcyclic GMP phosphodiesterase activity. The phosphorylated phosphodiesterase displayed linear kinetics for cyclic GMP hydrolysis, with Km = 1.6 amM and V.ax. = 11.9 nmol/min per mg. Addition of 20 units of the catalytic subunit of protein kinase A triggered a 6-fold stimulation of cyclic GMP phosphodiesterase activity, which was again due to a marked increase in the V..ax for cyclic GMP hydrolysis. The phosphodiesterase activity has Km = 1.6 /LM and V.ax. = 9.6 nmol/min per mg.
Inhibitor-sensitivity of the phosphorylated phosphodiesterase Addition of 40 units of the catalytic subunit of protein kinase A to the partially purified cyclic GMP phosphodiesterase triggers activation of cyclic GMP hydrolysis. We assessed whether the phosphorylated enzyme displayed altered sensitivity to inhibition by the type V-selective inhibitor Zaprinast. Zaprinast inhibited dose-dependently the cyclic GMP phosphodiesterase activity (Fig. 4, Table 3 ) with IC50 = 7.5 + 1.1 /sM-cyclic GMP.
Effect of protein kinase C Incubation of the partially purified preparation of cyclic GMP phosphodiesterase with protein kinase C did not significantly alter phosphodiesterase activity (results not shown).
DISCUSSION
We have partially purified the cylic GMP phosphodiesterase from high-speed supernatants of guinea-pig lung. The partially purified enzyme displayed kinetics and inhibitor-sensitivities which closely resembled those of the type V cyclic GMP-specific phosphodiesterase purified from both bovine and rat lung highspeed supernatants (Francis & Corbin, 1988; Thomas et al., 1990a) . For instance, Thomas et al. (1990a) determined a Km for cyclic GMP hydrolysis by the bovine lung isoform of 5.6 ,UM. In comparison, the cyclic GMP phosphodiesterase partially purified from guinea-pig lung high-speed supernatants has a Km of 2.2 + 0.2 #M. The bovine lung isoform is potently inhibited by Zaprinast, and likewise the guinea-pig lung phosphodiesterase is also markedly inhibited by this drug. Zaprinast is also a potent inhibitor of the type I Ca2+/calmodulin-stimulated cyclic GMP phosphodiesterase (Souness et al., 1989) . We suggest that the isoenzyme partially purified from guinea-pig lung is not a Ca2+/calmodulin-activated type I phosphodiesterase, since Ca2" and calmodulin did not stimulate cyclic GMP phosphodiesterase activity. The type I isoenzyme also displays specificity for cyclic AMP, whereas the lung isoform exclusively hydrolyses cyclic GMP. The most definitive evidence that the guinea-pig lung cyclic GMP phosphodiesterase is a type V isoenzyme is that isobutylmethylxanthine stimulates cyclic GMP binding to the enzyme. This is an established characteristic of type V phosphodiesterases (Francis & Corbin, 1988) . The ability of isobutylmethylxanthine to promote cyclic GMP binding while eliciting inhibition of cyclic GMP hydrolysis is due to enhanced binding at a non-catalytic site (Francis & Corbin, 1988) .
The partially purified cyclic GMP phosphodiesterase from guinea-pig lung is a substrate for phosphorylation by the catalytic subunit of protein kinase A. We have based this conclusion on the dose-dependent activation of cyclic GMP phosphodiesterase activity. Thomas et al. (1990b) observed that the bovine lung type V phosphodiesterase was a substrate for protein kinase A, although no activity change was detected upon phosphorylation of the isoenzyme. Cyclic GMP appeared to enhance the susceptibility of the isoenzyme to act as a substrate for protein kinase A, but did not enhance stimulation of phosphodiesterase activity. Likewise, the isoenzyme is also a substrate for protein kinase G. The protein kinase G-dependent phosphorylation of the isoenzyme occurs at the same site as that for protein kinase A, albeit with a faster rate. The present study therefore supports the notion that the type V isoenzyme is a substrate for protein kinase A, although in addition we have observed a marked activation of cyclic GMP hydrolysis. That activation results from a marked increase in the V..ax for cyclic GMP hydrolysis.
Consequently, the sensitivity to inhibition by Zaprinast is apparently decreased. This mechanism of activation of cyclic GMP phosphodiesterase activity is similar to the cyclic AMP-dependent activation of the type III cyclic AMP phosphodiesterase activity (Loten et al., 1978; Kilgour et al., 1989) . These observations may therefore reflect a generalized mechanism by which protein kinase A-mediated phosphorylation of phosphodiesterase results in a marked increase in catalytic efficiency. In contrast, protein kinase C had no effect on cyclic GMP hydrolysis by the partially purified cyclic GMP phosphodiesterase from guinea-pig lung. Again, these results are in accord with those of Thomas et al. (1990b) , where the type V bovine lung isoenzyme was shown to be a very poor substrate for protein kinase C.
These results suggest that the guinea-pig lung type V phosphodiesterase may be a substrate for protein kinase A in cells. The potent activation of cyclic GMP hydrolysis as a consequence of phosphorylation would have a significant effect on both basal and agonist-stimulated intracellular cyclic GMP levels. The change in the Vmax for cyclic GMP hydrolysis would have a substantial effect on cyclic GMP degradation in these cells. We have previously shown (Bums et al., 1991) that the lung type V isoenzyme appears to perform an important role in suppressing cyclic GMP levels in airways, since Zaprinast is capable of uncoupling pre-contracted airway smooth muscle via inhibition of the type V isoenzyme. There is substantial evidence to support the notion that elevated intracellular levels of both cyclic AMP and cyclic GMP can provoke excitation-contraction uncoupling (Torphy et al., 1988; Harris et al., 1989; Nakatsu & Diamond, 1989) , although it is ill-defined if these agents do so via similar or different mechanisms. Our results imply that there may be crosstalk between the cyclic GMP and cyclic AMP signalling cascades. However, the implied necessity for why suppressed cyclic GMP levels are produced upon elevation of intracellular cyclic AMP, and the physiological significance of this, require further study. One possibility is that two pools of cyclic GMP exist in lung cells. One elicits uncoupling ofexcitation-contraction coupling, whereas the other serves to inhibit cyclic AMP accumulation. Thus, as soon as cyclic AMP levels in these cells reach a sufficient value to promote protein kinase A activation, the type V phosphodiesterase hydrolyses the inhibitory cyclic GMP pool. This would allow greater amplification of cyclic AMP accumulation in response to /J-adrenoceptor agonists. In support of this notion, contractile agonists, while promoting mobilization of intracellular Ca2+, also promote cyclic GMP accumulation (Nakatsu & Diamond, 1989) . Indeed, for certain agonists such as methacholine, there exists a reciprocal antagonism between muscarinic tone and relaxation by agents that increase cyclic AMP (Torphy et al., 1988) , and this may be related to the extent ofmethacholineinduced cyclic GMP accumulation.
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